Running a treatment trial mid-outbreak, rather than after it, is only possible because eastern DRC has now weathered enough Ebola outbreaks to have real clinical trial infrastructure in place — a grim form of accumulated institutional capacity. Whether that capacity survives the gap until the next outbreak remains the harder, less-funded question.